LncRNA ANRIL Regulates Ovarian Cancer Progression and Tumor Stem Cell-Like Characteristics via miR-324-5p/Ran Axis

Wang, Ke; Hu, Yuxia; Zhao, Ye; Ye, Cong

doi:10.2147/ott.s273614

Cited by 6 publications

(3 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As scientists pushing the boundaries to reveal new insights, it has been revealed that lncRNA can be utilized as diagnostic and prognostic factors. Nevertheless, only limited number of lncRNAs have been directly involved in the tumorgenesis of leukemia [19,20]. For instance, ANRIL which is up-regulated in the BM samples collected from AML patients is negatively correlated with expression of miR-34a, a tumor suppressor markedly declined in individuals struggling with AML [21].…”

Section: Discussionmentioning

confidence: 99%

SNHG14 lncRNA as a tumor suppressor in adult non-M₃ AML patients; The diagnostic biomarker

Seifpour

Atashi

Zomorod

et al. 2023

Preprint

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is one of the most common adult blood malignancies that engages hematopoietic myeloid progenitors. A large number of studies have shown the involvement of long non-coding RNAs (lncRNAs) in AML pathogenesis. This study aimed to investigate the expression profile of lnRNA SNHG14 and its role in adult non-M₃ AML pathogenesis, clinical features, and diagnosis. We compared the expression level of SNHG14 by qRT-PCR technique between bone marrow (BM) samples obtained from 50 adult non-M₃ AML patients and 49 healthy controls. We also investigate the correlation between clinicopathological characteristics of AML patients with low and high SNHG14 expression. The expression level of SNHG14 was significantly decreased in BM tissues of adult non-M₃ AML patients compared with healthy controls. Patients with low expression levels of SNHG14 were associated with poor overall survival (OS), while no correlation was observed between low expression levels of SNHG14 and relapse free survival (RFS). Thus, our findings suggest that SNHG14 expression has the potential to be a biomarker for diagnosing adult non-M₃ AML patients. Put together, our findings suggest that lncRNA SNHG14 could be used as a potential diagnostic biomarker and may provide insights into novel therapeutic targets in adult non-M₃ AML patients.

show abstract

Section: Discussionmentioning

confidence: 99%

SNHG14 lncRNA as a tumor suppressor in adult non-M₃ AML patients; The diagnostic biomarker

Seifpour

Atashi

Zomorod

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…ANRIL, a long non-coding RNA located in a genetic desert with a high prevalence of SNPs [ 55 , 56 , 57 ] (to date, many of these SNPs have been related to a higher prevalence of cancer), interacts with both PRC1 through the CBX7 subunit and PRC2 through the SUZ12 subunit to repress the expression of the CDKN2A/B locus and thus maintaining its silence. This locus is downregulated in many types of cancer, such as leukemia, breast cancer, pancreatic cancer, ovarian cancer, and gliomas [ 58 , 59 , 60 , 61 , 62 ]. Repression of the CDNK2A/B locus by ANRIL increases the cell proliferation of malignant cells, promoting progression and metastasis.…”

Section: Genetic and Epigenetic Contributions Of Lncrna Dysregulation...mentioning

confidence: 99%

Molecular Mechanisms of lncRNAs in the Dependent Regulation of Cancer and Their Potential Therapeutic Use

García-Padilla

Dueñas

García‐López

et al. 2022

IJMS

View full text Add to dashboard Cite

Deep whole genome and transcriptome sequencing have highlighted the importance of an emerging class of non-coding RNA longer than 200 nucleotides (i.e., long non-coding RNAs (lncRNAs)) that are involved in multiple cellular processes such as cell differentiation, embryonic development, and tissue homeostasis. Cancer is a prime example derived from a loss of homeostasis, primarily caused by genetic alterations both in the genomic and epigenetic landscape, which results in deregulation of the gene networks. Deregulation of the expression of many lncRNAs in samples, tissues or patients has been pointed out as a molecular regulator in carcinogenesis, with them acting as oncogenes or tumor suppressor genes. Herein, we summarize the distinct molecular regulatory mechanisms described in literature in which lncRNAs modulate carcinogenesis, emphasizing epigenetic and genetic alterations in particular. Furthermore, we also reviewed the current strategies used to block lncRNA oncogenic functions and their usefulness as potential therapeutic targets in several carcinomas.

show abstract

“…In addition, CHRF contributes to cisplatin resistance of ovarian cancer cells by regulating EMT and STAT3 signaling via miR-10b (Tan et al, 2020). ANRIL could modulate the progression, drug resistance and tumor stem celllike characteristics of ovarian cancer cells via miR-324-5p/Ran Axis (Wang K. et al, 2021). Some tumor suppressor lncRNAs can reverse platinum drug resistance of ovarian cancer.…”

Section: Lncrnas and Therapy Resistancementioning

confidence: 99%

The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer

et al. 2021

View full text Add to dashboard Cite

Ovarian cancer is one of the most common gynecological malignancies with highest mortality rate among all gynecological malignant tumors. Advanced ovarian cancer patients can obtain a survival benefit from chemotherapy, including platinum drugs and paclitaxel. In more recent years, the administration of poly-ADP ribose polymerase inhibitor to patients with BRCA mutations has significantly improved the progression-free survival of ovarian cancer patients. Nevertheless, primary drug resistance or the acquisition of drug resistance eventually leads to treatment failure and poor outcomes for ovarian cancer patients. The mechanism underlying drug resistance in ovarian cancer is complex and has not been fully elucidated. Interestingly, different non-coding RNAs (ncRNAs), such as circular RNAs, long non-coding RNAs and microRNAs, play a critical role in the development of ovarian cancer. Accumulating evidence has indicated that ncRNAs have important regulatory roles in ovarian cancer resistance to chemotherapy reagents and targeted therapy drugs. In this review, we systematically highlight the emerging roles and the regulatory mechanisms by which ncRNAs affect ovarian cancer chemoresistance. Additionally, we suggest that ncRNAs can be considered as potential diagnostic and prognostic biomarkers as well as novel therapeutic targets for ovarian cancer.

show abstract

LncRNA ANRIL Regulates Ovarian Cancer Progression and Tumor Stem Cell-Like Characteristics via miR-324-5p/Ran Axis

Cited by 6 publications

References 45 publications

SNHG14 lncRNA as a tumor suppressor in adult non-M₃ AML patients; The diagnostic biomarker

SNHG14 lncRNA as a tumor suppressor in adult non-M₃ AML patients; The diagnostic biomarker

Molecular Mechanisms of lncRNAs in the Dependent Regulation of Cancer and Their Potential Therapeutic Use

The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer

Contact Info

Product

Resources

About